Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Dual Targeting of Cell-Cycle Checkpoint Kinase and Unfolded Protein Response As a Novel Therapeutic Approach for High-Risk Multiple Myeloma with TP53 Deletion or Mutations

Yuka Tanaka, MD, Takayuki Tabayashi, MD PhD, Yasuyuki Takahashi, MD PhD, Yuta Kimura, MD, Tatsuki Tomikawa, MD PhD, Junichi Watanabe, MD PhD, Tomoe Anan-Nemoto, MD PhD, Morihiko Sagawa, MD PhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, Masahiro Kizaki, MD PhD

Blood (2018) 132 (Supplement 1): 5613.

https://doi.org/10.1182/blood-2018-99-116247

Published: 2018

Journal Articles

The Absolute Count of Lymphocytes Is a Strong Predictive Factor for Relapse/Regrowth Events and Outcomes in Patients with Regressive Methotrexate-Associated Lymphoproliferative Disorders

Michihide Tokuhira, Yuta Kimura, MD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD PhD, Tatsuki Tomikawa, MD PhD, Junichi Watanabe, MD PhD, Tomoe Anan-Nemoto, MD PhD, Morihiko Sagawa, MD PhD, Shuji Momose, MD PhD, Morihiro Higashi, MD PhD, Tabayashi Takayuki, MD PhD, Reiko Nakaseko, MD PhD, Jun-ichi Tamaru, MDPhD, Masahiro Kizaki, MDPhD

Blood (2018) 132 (Supplement 1): 1589.

https://doi.org/10.1182/blood-2018-99-114382

Published: 2018

Journal Articles

Multiple Myeloma Patients with Lenalidomide-Associated Skin Rash Have a Favorable Prognosis

Ayumi Kojima, Yuka Tanaka, Yuta Kimura, Daisuke Tsuchimoto, Rina Etani, Tetsufumi Kanematsu, Kenji Miyazawa, Akiya Mori, Atsuhiko Naruse, Hirokazu Nagai, MD PhD

Blood (2016) 128 (22): 4532.

https://doi.org/10.1182/blood.V128.22.4532.4532

Published: 2016

Journal Articles

CD14-CD15+, Possible Cells Are Potent Myeloid-Derived Suppressor Cells, Which Affect the Pathogenesis of Induction and Regression in Methotrexate-Mediated Lymphoproliferative Disorders

Michihide Tokuhira, MD PhD, Shuntaro Saito, MD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Tomoe Anan, MD, PhD, Shuji Momose, MD PhD, Morihiro Higashi, MD, PhD, Takayuki Shimizu, MD PhD, Takehiko Mori, MD PhD, Takayuki Tabayashi, MD PhD, Reiko Watanabe, MD PhD, Jun-ichi Tamaru, MD, PhD, Shinichiro Okamoto, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 2946.

https://doi.org/10.1182/blood.V128.22.2946.2946

Published: 2016

Journal Articles

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

Takayuki Tabayashi, MD PhD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Morihiko Sagawa, MD PhD, Tomoe Anan-Nemoto, MDPhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 3256.

https://doi.org/10.1182/blood.V128.22.3256.3256

Published: 2016

Journal Articles

An Epigenetic Mechanism Of Imatinib Via Demethylation Of MiR-203

Tsukuru Umemura, MD, PhD, Tatsuki Shibuta, Emi Honda, M.D., Hiromichi Shiotsu, Yuka Tanaka, Shalini Vellasamy, Motoaki Shiratsuchi

Blood (2013) 122 (21): 3766.

https://doi.org/10.1182/blood.V122.21.3766.3766

Published: 2013

Journal Articles

Blockade of invariant TCR-CD1d interaction specifically inhibits antibody production against blood group A carbohydrates

Hirofumi Tazawa, Toshimitsu Irei, Yuka Tanaka, Yuka Igarashi, Hirotaka Tashiro, Hideki Ohdan

Blood (2013) 122 (15): 2582–2590.

https://doi.org/10.1182/blood-2012-02-407452

Published: 2013

Includes: Supplemental data

Journal Articles

MicroRNA-Ago2 Complex in Mature Human Red Blood Cells.

Tsukuru Umemura, MD, PhD, Yuka Tanaka, Megumi Fujisaki, Shizuka Masaki, Hiromichi Shiotsu, Kanitta Srinoun, Suthat Fucharoen, Yasunobu Abe, Hisako Ichihara, Hiroyuki Toh, Hajime Hisaeda

Blood (2009) 114 (22): 4042.

https://doi.org/10.1182/blood.V114.22.4042.4042

Published: 2009

Journal Articles

The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation

Toshimitsu Irei, Hideki Ohdan, Wendy Zhou, Kohei Ishiyama, Yuka Tanaka, Kentaro Ide, Toshimasa Asahara

Blood (2007) 110 (13): 4567–4575.

https://doi.org/10.1182/blood-2007-04-082719

Published: 2007

NARROW

Dual Targeting of Cell-Cycle Checkpoint Kinase and Unfolded Protein Response As a Novel Therapeutic Approach for High-Risk Multiple Myeloma with TP53 Deletion or Mutations

The Absolute Count of Lymphocytes Is a Strong Predictive Factor for Relapse/Regrowth Events and Outcomes in Patients with Regressive Methotrexate-Associated Lymphoproliferative Disorders

Multiple Myeloma Patients with Lenalidomide-Associated Skin Rash Have a Favorable Prognosis

CD14-CD15+, Possible Cells Are Potent Myeloid-Derived Suppressor Cells, Which Affect the Pathogenesis of Induction and Regression in Methotrexate-Mediated Lymphoproliferative Disorders

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

An Epigenetic Mechanism Of Imatinib Via Demethylation Of MiR-203

Blockade of invariant TCR-CD1d interaction specifically inhibits antibody production against blood group A carbohydrates

MicroRNA-Ago2 Complex in Mature Human Red Blood Cells.

The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only